Chemical Component Summary

Identifiers2-oxidanylidenepentanedioic acid
FormulaC5 H6 O5
Molecular Weight146.098
Isomeric SMILESC(CC(=O)O)C(=O)C(=O)O

Chemical Details

Formal Charge0
Atom Count16
Chiral Atom Count0
Bond Count15
Aromatic Bond Count0

Drug Info: DrugBank

DrugBank IDDB08845 
NameOxogluric acid
  • experimental
  • investigational
  • nutraceutical
DescriptionOxogluric acid (α-Ketoglutarate) is not approved for any indication in the world but is an investigational drug in the United States. In the United States a phase I clinical trial is investigating whether oxogluric acid precursors found in nutritional supplements can benefit patients with the metabolic disorder propionic acidemia. Oxogluric acid is sold as a dietary supplement to athletes to improve their performance by helping to remove excess ammonia, but it is not officially approved for this indication and only experimental studies have shown a reduction in ammonia by oxogluric acid in hemodialysis patients. Physiologically, oxogluric acid acts in the Krebs cycle as an intermediate, is involved in transamination reactions during the metabolism of amino acids, forms glutamic acid by combining with ammonia, and reduces nitrogen by combining with it as well. Several experimental studies have also shown that administration of oxogluric acid helped attenuate the decreased synthesis of muscle protein that is often seen post-surgery.
  • 2-oxopentanedioic acid
  • 2-Ketoglutaric acid
  • Oxogluric acid
  • Oxoglurate
  • 2-oxoglutaric acid
Indicationα-α-Ketoglutarate is not approved for any indication in the world but is an investigational drug in the United States. The potential indications for α-Ketoglutarate are in patients with the metabolic disorder propionic acidemia and in trauma patients with muscle loss.
  • Acids, Acyclic
  • Dicarboxylic Acids
  • Glutarates
  • Keto Acids
  • Ketoglutaric Acids
CAS number328-50-7

Drug Targets

NameTarget SequencePharmacological ActionActions
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682

Related Resource References

Resource NameReference